Saluda Medical – Page 2 – BioScience Managers

Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology

21st December 2019/in Saluda Medical

Link to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]

Regulatory approval next hurdle for Saluda Medical

26th July 2019/in Saluda Medical

Link to Full Article Regulatory approval is the next major hurdle facing Saluda Medical, the biotech company which is led by Cochlear’s former chief technology officer and was responsible for the biggest domestic life sciences capital raising of the last fiscal year. Saluda Medical said in June it had raised $US75 million ($106 million) from […]

Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group

28th June 2019/in Saluda Medical

Artarmon, NSW, Australia – June 28, 2019 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that it has secured $75 million in equity financing from Boston Scientific Corporation (NYSE: BSX) and Redmile Group LLC to fund the final stages of development through commercialization of its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for […]

Saluda Medical Secures Debt Financing From Medtronic

27th June 2019/in Saluda Medical

Proceeds to fund continued development of Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System Evoke Trial Validates Level I Evidence Achieved Through First Double-Blind Randomized U.S. Pivotal Study in SCS Proceeds to fund continued development of Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System Evoke Trial Validates Level I Evidence Achieved Through First Double-Blind Randomized U.S. […]

Saluda Medical featured in Nature Journal

14th July 2016/in Portfolio Companies, Saluda Medical

Biomedicine: Move over, morphine James Mitchell Crow Nature 535, S4–S6 (14 July 2016) Published online 13 July 2016 Link here.

Saluda Medical – Aussie innovation gives hope to back pain sufferers

14th October 2015/in Portfolio Companies, Saluda Medical

October 14, 2015: 9NEWS spoke exclusively to the first patient to undergo the new treatment that is giving hope to sufferers of back pain. Read more at http://www.9news.com.au/national/2015/10/14/19/04/aussie-innovation-gives-hope-to-back-pain-sufferers#b0dfx4DwJTTVgPDM.99

Saluda spinal implant for pain relief heralded as ‘breakthrough’

14th October 2015/in Portfolio Companies, Saluda Medical

Harriet Alexander Sydney Morning Herald. Published: October 14, 2015 6:34PM Every minute of the night and day, for decades, Jaswir Grewal was in pain. The constant ache in his back forced him to leave his jobs as a mechanic and banana grower. The pain troubled his sleep, made him irritable with his wife, depressed about his […]

BioScience Managers $5M Cornerstone Investment in Saluda Medical

20th February 2015/in BioSciences Managers, Saluda Medical

Potential breakthrough treatment for chronic pain Part of $10m capital raising BioScience Managers achieved a 24.7% IRR in its previous fund – top decile performance of international private equity and venture capital fund managers. 20 February 2015, Melbourne, Australia: Leading healthcare fund manager BioScience Managers has invested $5 million in novel chronic pain treatment company Saluda […]

Saluda announces Series B funding

6th February 2015/in Portfolio Companies, Saluda Medical

Saluda Medical secures $10 million in new financing New funding secured for Saluda Medical is set to open the next chapter in commercialising breakthrough treatment of chronic pain. Link here. Friday, 20 February 2015: Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain – […]